Covidien's Fortrex PTA Balloon Catheter Receives FDA Nod - Analyst Blog

An image of stock prices rising and declining in value
Credit: Shutterstock photo

Covidien plc ( COV ) recently obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Fortrex over-the-wire percutaneous transluminal angioplasty (PTA) balloon catheter. Fortrex PTA balloon catheter is designed for both maintaining arteriovenous (AV) access for hemodialysis and treating peripheral artery diseases.

Hemodialysis is a procedure that filters waste and removes extra fluid from the blood in patients suffering from chronic kidney disease or end stage renal failure. AV access sites are used to provide hemodialysis to patients. However, plaque blockages at the dialysis site can limit access.

Engineered to maximize the inflation of the balloon to break up the blockages and open the vessel, Covidien's Fortrex PTA balloon provides better hemodialysis access. A high pressure solution is used to crack the short, fibrous lesions that can block AV access.

The balloon's unique material and design also provide clinicians with optimized balloon delivery, predictable and targeted treatment and procedural efficiency. The FDA clearance of this device builds on Covidien's existing PTA portfolio, providing clinicians with access to an advanced solution to improve AV access in patients being treated with hemodialysis.

Covidien's shares closed little changed at $99.32 yesterday. This Mansfield-based company has delivered a healthy return of roughly 46% so far this year.

Earlier this month, Covidien signed a deal to sell its Stellarex drug-coated angioplasty balloon (DCB) platform to Spectranetics for $30 million. Covidien decided to divest its Stellarex DCB platform so that the pending $43 billion merger with Medtronic, Inc. ( MDT ) can commence under the antitrust law.

Designed to treat peripheral arterial disease, Stellarex DCB is part of Covidien's vascular product line. An FDA sanction for this device is expected in 2017.

Covidien faces significant competition from the likes of Becton, Dickinson and Co. ( BDX ) and CR Bard Inc. ( BCR ), which is major headwind in the near term. Notably, C.R. Bard's Lutonix 035 DCB Catheter became the first drug-coated balloon to be cleared by the FDA for percutaneous transluminal angioplasty in Oct 2014.

Currently, Covidien carries a Zacks Rank #3 (Hold).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BARD C R INC (BCR): Free Stock Analysis Report

MEDTRONIC (MDT): Free Stock Analysis Report

COVIDIEN PLC (COV): Free Stock Analysis Report

BECTON DICKINSO (BDX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More